CIPM Expands Drug Funding and Indications

The Interministerial Commission on Drug Prices (CIPM) proposed at its meeting on January 28th, 2026, the full or partial funding of three new drugs and several extensions of indication for others already authorized and previously funded for various conditions. Among the decisions adopted are treatments for rare diseases, respiratory conditions, and various solid tumors, as well as an expansion of the use of a drug for hemophilia A in the pediatric population

According to the meeting’s minutes, one of the three proposed medications for funding is classified as an orphan drug, while the other two address indications in therapeutic areas with specific clinical needs. Furthermore, the CIPM discussed funding for new indications for two medications that were already funded for other indications, thus expanding their scope of use within the National Health System.

Among the newly added medications for which the CIPM proposed full or partial funding is Andembry (garadacimab). This medication is indicated for the routine prevention of recurrent hereditary angioedema attacks in adult and adolescent patients 12 years of age and older. The proposal is limited to this specific indication and the population defined in the agreement.

Another of the included medications is Skyclarys (omaveloxolone), identified in the document with the symbol corresponding to an orphan drug. The CIPM proposed its funding for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 and over. Friedreich’s ataxia is a rare, inherited disease, and this proposal is limited to the indication and age range specified in the agreement.

The third newly funded drug is Zanosar (streptozocin). In this case, the proposal refers to the systemic treatment of adult patients with inoperable, advanced or metastatic, progressive or symptomatic, well-differentiated neuroendocrine tumors of pancreatic origin, classified as G1 or G2. The proposed use includes its administration in combination with 5-fluorouracil.

Funded indication extensions by CIPM

In addition to new medicines, the CIPM proposed funding for new indications for drugs that were already authorized and funded for other indications. One of these is Tezspire (tezepelumab), for which funding was agreed upon as an add-on treatment to intranasal corticosteroids.

This new indication for Tezspire is for the treatment of adult patients with chronic rhinosinusitis with severe nasal polyposis, in cases where systemic corticosteroid therapy or surgery does not provide adequate disease control. The proposal defines both the type of pathology and the profile of eligible patients.

The other drug with newly funded indications is Keytruda (pembrolizumab), which was the focus of several decisions made at the January meeting. First, funding was proposed for Keytruda in combination with carboplatin and paclitaxel as first-line treatment for advanced or recurrent primary endometrial cancer in adult women who are candidates for systemic therapy.

Additional Oncology Indications

In the oncology field, the CIPM also proposed funding for Keytruda in combination with chemoradiotherapy, defined as external beam radiotherapy followed by brachytherapy, for the treatment of locally advanced cervical cancer. This indication is limited to patients with FIGO 2014 stage III to IVA disease who have not received prior definitive treatment

Another newly funded indication for Keytruda is its use in combination with axitinib as a first-line treatment for advanced renal cell carcinoma in adults. This expansion is in addition to the existing indications for the drug in other types of solid tumors.

The meeting minutes also state that, in addition to the new indications, an agreement was reached to remove a restriction previously applied to two indications for this medication. Specifically, the limitation affecting certain patients receiving first-line treatment for metastatic non-small cell lung cancer was eliminated.

Removal of usage restrictions

The two indications for Keytruda for which the restriction was lifted correspond, firstly, to the first-line treatment of metastatic squamous non-small cell lung cancer in adults, in combination with carboplatin and paclitaxel or nab-paclitaxel. Secondly, to the first-line treatment of metastatic non-squamous non-small cell lung cancer in adults, in combination with pemetrexed and platinum-based chemotherapy, whose tumors do not have EGFR or ALK mutations.

As detailed in the document, the removed restriction limited the use of the drug to patients with PD-L1 expression below 50 percent, negative or impossible to perform, for whom the current therapy was chemotherapy. With this decision, this limitation no longer applies to the aforementioned indications.

Extension to pediatric population

Along with agreements on new medicines and extensions of indications for adults, the CIPM also addressed the funding of an extension of indications for the pediatric population. In this case, funding was agreed upon for the expanded use of the medicine Jivi (damoctocog alfa pegol).

The extension of the indication refers to the treatment and prophylaxis of bleeding in patients seven years of age and older with hemophilia A, defined as a congenital deficiency of factor VIII, who have been previously treated. The specific proposal defines both the minimum age and the profile of patients included.

__

(Featured image by Zulfugar Karimov via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.